(Journal Article): Differential Roles of Costimulatory Signaling Pathways in Type 1 Diabetes Mellitus
 
Boehm BO, Bluestone JA (Division of Endocrinology and Diabetes, Department of Internal Medicine, University of Ulm, Germany, bernhard.boehm@medizin.uni-ulm.de )
 
IN: Rev Diabetic Stud 2004; 1(4):156-164
Impact Factor(s) of Rev Diabetic Stud: 0.125 (2006)

Fulltext:    HTML  PDF

ABSTRACT: Not available

TYPE OF PUBLICATION: Review

REFERENCES:

1. Jerne NK. Towards a network theory of the immune system. Annals d ‘Imunnologie (Institute Pasteur) 1974. 125 C:373-389.
2. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002. 347:911-920.
3. Durinovic-Bello I, Schlosser M, Riedl M, Maisel N, Rosinger S, Kalbacher H, Deeg M, Ziegler M, Elliott J, Roep BO, Karges W, Boehm BO. Pro- and anti-inflammatory cytokine production by autoimmune T cells against preproinsulin in HLA-DRB1*04, DQ8 Type 1 diabetes. Diabetologia 2004. 47:439-450.
4. Roep BO, Atkinson MA, Van Endert PM, Gottlieb PA, Wilson SB, Sachs JA. Autoreactive T cell responses in insulin-dependent (type 1) diabetes mellitus. Report of the first international workshop for standardization of T cell assays. J Autoimmun 1999. 13:267-282.
5. June CH, Ledbetter JA, Linsley PS, Thompson CB. Role of the CD28 receptor in T-cell activation. Immunol Today 1990. 11:211–216.
6. Greenfield EA, Nguyen KA, Kuchroo VK. CD28/B7 costimulation: a review. Crit Rev Immunol 1998. 18(5):389-418.
7. Bour-Jordan H, Salomon BL, Thompson HL, Szot GL, Bernhard MR, Bluestone JA. Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J Clin Invest 2004. 114(7):979-987.
8. Noel PJ, Boise LH, Thompson CB. Regulation of T cell activation by CD28 and CTLA4. Adv Exp Med Biol 1996. 406:209-217.
9. Grakoui A, Bromley SK, Sumen C, Davis MM, Shaw AS, Allen PM, Dustin ML. The immunological synapse: a molecular machine controlling T cell activation. Science 1999. 285:221-227.
10. Huppa JB, Davis MM. T-cell-antigen recognition and the immunological synapse. Nat Rev Immunol 2003, 3:973-983.
11. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002. 2:116-126.
12. Lenschow DJ, Herold KC, Rhee L, Patel B, Koons A, Qin HY, Fuchs E, Singh B, Thompson CB, Bluestone JA. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 1996. 5(3):285-293.
13. Nakae S, Asano M, Horai R, Sakaguchi N, Iwakura Y. IL-1 enhances T cell-dependent antibody production through induction of CD40 ligand and OX40 on T cells. J Immunol 2001. 167(1):90-79.
14. Durie FH, Foy TM, Masters SR, Laman JD, Noelle RJ. The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today 1994. 15(9):406-411.
15. Anand S, Chen L. Control of autoimmune diseases by the B7-CD28 family molecules. Curr Pharm Des 2004. 10:121-128.
16. McAdam AJ, Chang TT, Lumelsky AE, Greenfield EA, Boussiotis VA, Duke-Cohan JS, Chernova T, Malenkovich N, Jabs C, Kuchroo VK, et al. Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells. J Immunol 2000, 165(9):5035-5040.
17. Swallow MM, Wallin JJ, Sha WC. B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha. Immunity 1999. 11(4):423-432.
18. Peach RJ, Bajorath J, Brady W, Leytze G, Greene J, Naemura J, Linsley PS. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J Exp Med 1994. 180(6):2049-2058.
19. Fallarino F, Fields PE, Gajewski TF. B7-1 engagement of cytotoxic T-lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J Exp Med 1998. 188(1):205-210.
20. Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, Straus D, Samelson LE, Thompson CB, Bluestone JA. Molecular basis of T cell inactivation by CTLA-4. Science 1998. 282(5397):2263-2266.
21. Chuang E, Fisher TS, Morgan RW, Robbins MD, Duerr JM, Vander Heiden MG, Gardner JP, Hambor JE, Neveu MJ, Thompson CB. The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A. Immunity 2000. 13(3):313-322.
22. Baroja ML, Vijayakrishnan L, Bettelli E, Darlington PJ, Chau TA, Ling V, Collins M, Carreno BM, Madrenas J, Kuchroo VK. Inhibition of CTLA-4 function by the regulatory subunit of serine/threonine phosphatase 2A. J Immunol 2002. 168(10):5070-5078.
23. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000. 192(7):1027-1034.
24. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001. 2(3):261-268.
25. Khoury SJ, Sayegh MH. The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity 2004. 20:529-538.
26. Khattri R, Auger JA, Griffin MD, Sharpe AH, Bluestone JA. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses. J Immunol 1999. 162(10):5784-5791.
27. Mandelbrot DA, McAdam AJ, Sharpe AH. B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). J Exp Med 1999. 189:435-440.
28. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995. 3:541-547.
29. Watts TH, DeBenedette MA. T cell co-stimulatory molecules other than CD28. Curr Opin Immunol 1999. 11:286-293.
30. Pociot F, McDermott MF. Genetics of type 1 diabetes mellitus. Genes Immun 2002. 3:235-349.
31. Redondo MJ, Eisenbarth GS. Genetic control of autoimmunity in type 1 diabetes and associated disorders. Diabetologia 2002. 45:605-622.
32. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003. 423:506-511.
33. Marron MP, Zeidler A, Raffel LJ, Eckenrode SE, Yang JJ, Hopkins DI, Garchon HJ, Jacob CO, Serrano-Rios M, Martinez Larrad MT, et al. Genetic and physical mapping of a type 1 diabetes susceptibility gene (IDDM12) to a 100-kb phagemid artificial chromosome clone containing D2S72-CTLA4-D2S105 on chromosome 2q33. Diabetes 2000. 49:492-499.
34. Mein CA, Esposito L, Dunn MG, Johnson GCL, Timms AE, Goy JV, Smith AN, Sebag-Montefiore L, Merriman ME, Wilson AJ, et al. A search for type 1 diabetes susceptibility genes in families from the United Kingdom. Nat Genet 1998. 19:297-300.
35. Kouki T, Sawai Y, Gardine CA, Fisfalen ME, Alegre ML, DeGroot LJ. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 2000. 165:6606-6611.
36. Vijayakrishnan L, Slavik JM, Illes Z, Greenwald RJ, Rainbow D, Greve B, Peterson LB, Hafler DA, Freeman GJ, Sharpe AH, Wicker LS, Kuchroo VK. An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity 2004. 20:563-575.
37. Magistrelli G, Jeannin P, Herbault N, Benoit De Coignac A, Gauchat JF, Bonnefoy JY, Delneste Y. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol 1999. 29(11):3596-3602.
38. Wicker LS, Chamberlain G, Hunter K, Rainbow D, Howlett S, Tiffen P, Clark J, Gonzalez-Munoz A, Cumiskey AM, Rosa RL, et al. Fine mapping, gene content, comparative sequencing, and expression analyses support Ctla4 and Nramp1 as candidates for Idd5.1 and Idd5.2 in the nonobese diabetic mouse. J Immunol 2004. 173(1):164-173.
39. Schwartz JC, Zhang X, Nathenson SG, Almo SC. Structural mechanisms of costimulation. Nat Immunol 2002. 3:427-434.
40. Pechhold K, Patterson NB, Blum C, Fleischacker CL, Boehm BO, Harlan DM. Low dose streptozotocin-induced diabetes in rat insulin promoter-mCD80-transgenic mice is T cell autoantigen-specific and CD28-dependent. J Immunol 2001. 166(4):2531-2539.
41. Pechhold K, Karges W, Blum C, Boehm BO, Harlan DM. Βeta-cell-specific CD80 (B7-1) expression disrupts tissue protection from autoantigen-specific CTL-mediated diabetes. J Autoimmun 2003. 20(1):1-13.
42. Havari E, Lennon-Dumenil AM, Klein L, Neely D, Taylor JA, McInerney MF, Wucherpfennig KW, Lipes MA. Expression of the B7.1 costimulatory molecule on pancreatic beta-cells abrogates the requirement for CD4 T cells in the development of type 1 diabetes. J Immunol 2004. 173:787-796.
43. Karges W, Pechhold K, Al Dahouk S, Riegger I, Rief M, Wissmann A, Schirmbeck R, Barth C, Boehm BO. Induction of autoimmune diabetes through insulin (but not GAD65) DNA vaccination in nonobese diabetic and in RIP-B7.1 mice. Diabetes 2002. 51(11):3237-3244.
44. Lenschow DJ, Ho SC, Sattar H, Rhee L, Gray G, Nabavi N, Herold KC, Bluestone JA. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995. 181(3):1145-1155.
45. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000. 12(4):431-440.
46. Rulifson IC, Sperling AI, Fields PE, Fitch FW, Bluestone JA. CD28 costimulation promotes the production of Th2 cytokines. J Immunol 1997. 158(2):658-665.
47. Bour-Jordan H, Grogan JL, Tang Q, Auger JA, Locksley RM, Bluestone JA. CTLA-4 regulates the requirement for cytokine-induced signals in T(H)2 lineage commitment. Nat Immunol 2003. 4(2):182-8.
48. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001. 19:225-252.
49. Eggena MP, Walker LS, Nagabhushanam V, Barron L, Chodos A, Abbas AK. Cooperative roles of CTLA-4 and regulatory T cells in tolerance to an islet cell antigen. J Exp Med 2004, 199:1725-1730.
50. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T-lymphocyte-associated antigen 4. J Exp Med 2000. 192(2):303-310.
51. Tang Q, Boden EK, Henriksen KJ, Bour-Jordan H, Bi M, Bluestone JA. Distinct roles of CTLA-4 and TGF-β-in CD4+CD25+ regulatory T cell function. Eur J Immunol 2004. 34(11):2996-3005.
52. Darabi K, Karulin AY, Boehm BO, Hofstetter HH, Fabry Z, LaManna JC, Chavez JC, Tary-Lehmann M, Lehmann PV. The third signal in T cell-mediated autoimmune disease? J Immunol 2004. 173:92-99.
53. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005. 17:1-14.
54. Lang KS, Recher M, Junt T, Navarini AA, Harris NL, Freigang S, Odermatt B, Conrad C, Ittner LM, Bauer S, et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med 2005. 11:138-145.
55. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, Williams GR, Becker JC, Hagerty DT, Moreland LW. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003. 349(20):1907-1915.
56. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, Candeloro P, Belladonna ML, Bianchi R, Fioretti MC, Puccetti P. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002. 3(11):1097-1101.
57. Boasso A, Herbeuval JP, Hardy AW, Winkler C, Shearer GM. Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells. Blood 2004, online pre-publishing October 2004.

Articles citing this article:

• Thomas D, Zaccone P, Cooke A. The Role of Regulatory T Cell Defects in Type I Diabetes and the Potential of these Cells for Therapy. Rev Diabetic Stud 2005. 2: 9-18.
  » Diabetes OD » Reversal/Prevention of Diabete... » T1DM » Re-establishing Tolerance » Modifying Immunity » Journal Article 
• Sia C, Weinem M. Genetic Susceptibility to Type 1 Diabetes in the Intracellular Pathway of Antigen Processing - A Subject Review and Cross-Study Comparison. Rev Diabetic Stud 2005. 2: 40-52.
  » Diabetes OD » Diabetes Pathogenesis » T1DM » Autoimmunity » Defects in Self-Tolerance » MHC class I Antigen Presentati... » Intracellular Antigen Processi... » Journal Article